Senti Biosciences, Inc. (SNTI) Key Metrics
SNTI valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $7.0M
- Enterprise value
- $24.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 127.4
- Price / book
- 5.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.22
SNTI key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSNTI returns How much profit the business earns on the capital it uses.
SNTI financial health Debt, liquidity and how easily interest is covered.
SNTI efficiency & capital use Working capital cycle and where the cash goes.
SNTI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SNTI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SNTI cash returned to shareholders
SNTI key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Share price at fiscal year-end | $1.04 | $3.51 | $6.60 | $14.10 | $98.60 | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −393.4% | −114.1% | −73.2% | −48.8% | — | — | −117.8% |
| Return on invested capital (ROIC) | −346.3% | −121.1% | −109.0% | −120.2% | — | — | — |
| Return on assets (ROA) | −82.4% | −48.6% | −47.3% | −33.0% | −76.3% | −47.2% | −59.0% |
| Return on tangible assets | −119.9% | −54.0% | −59.5% | −25.3% | −57.2% | −41.1% | −59.0% |
| Financial health | |||||||
| Total debt | $28.9M | $33.6M | $37.7M | $37.1M | $22.7M | $14.0M | — |
| Cash & short-term investments | $16.4M | $48.3M | $35.9M | $98.6M | $56.0M | $30.5M | $17.8M |
| Net debt | $12.5M | −$14.6M | $1.7M | −$61.5M | −$33.3M | −$16.5M | −$17.8M |
| Debt / equity | 5.17 | 1.31 | 0.56 | 0.29 | 0.38 | — | — |
| Debt / assets | 0.56 | 0.34 | 0.32 | 0.21 | 0.24 | 0.29 | — |
| Current ratio | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 | 6.52 | 4.36 |
| Quick ratio | 1.67 | 4.46 | 5.62 | 5.50 | 3.86 | 6.51 | 4.36 |
| Interest coverage | — | — | — | -18.0 | — | -280.6 | — |
| Working capital | $9.3M | $45.8M | $58.5M | $84.5M | $44.2M | $26.8M | $14.5M |
| Invested capital | $18.1M | $11.0M | $68.7M | $65.8M | $27.1M | −$75.2M | $136,000 |
| Tangible asset value | $5.6M | $25.6M | $66.9M | $127.3M | $60.4M | −$58.7M | $18.0M |
| Net current asset value | −$22.4M | −$13.2M | $18.6M | $49.0M | $22.4M | −$75.3M | $883,000 |
| Capital allocation | |||||||
| Dividends paid | — | — | $404,000 | $5.2M | $3,894 | — | — |
| Share buybacks (net) | — | — | $0 | $0 | — | — | — |
| Capex / revenue | 890.9% | — | 608.6% | 965.3% | 241.9% | 294.7% | 2,348.2% |
| Capex / depreciation | 0.05 | 0.00 | 2.22 | 10.55 | 1.84 | 0.58 | 1.43 |
| Stock-based compensation / revenue | 25,936.4% | — | 488.9% | 382.5% | 100.2% | 69.0% | 241.2% |
| R&D / revenue | 170,845.5% | — | 1,625.4% | 794.8% | 958.4% | 4,049.7% | 17,087.1% |
| SG&A / revenue | 118,922.7% | — | 1,973.9% | 953.1% | 927.5% | 2,361.4% | 8,638.8% |
| Efficiency | |||||||
| Days sales outstanding | 28,204.5 | — | 1,691.2 | 47.2 | 63.7 | 183.0 | 334.9 |
| Days of inventory on hand | — | — | — | 274.3 | 159.3 | 0.6 | — |
| Days payables outstanding | 220.6 | — | 122.4 | 347.0 | 369.9 | 24.1 | 30.1 |
| Cash conversion cycle (days) | 27,983.9 | — | 1,568.8 | -25.5 | -146.8 | 159.4 | 304.9 |
| Receivables turnover | 0.01 | 0.00 | 0.22 | 7.73 | 5.73 | 1.99 | 1.09 |
| Payables turnover | 1.65 | — | 2.98 | 1.05 | 0.99 | 15.12 | 12.13 |
| Inventory turnover | — | — | — | 1.33 | 2.29 | 638.24 | — |
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.03 | 0.03 | 0.01 | 0.00 |
| Average receivables | $1.7M | $9.8M | $9.2M | $554,500 | $400,000 | $197,500 | $78,000 |
| Average payables | $2.2M | $1.4M | $1.8M | $3.7M | $3.1M | $1.1M | $1.2M |
| Average inventory | — | $335,000 | — | $2.9M | $1.3M | $25,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SNTI's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SNTI valuation and financial ratios
Senti Biosciences earned a return on equity of −393.4% and a return on invested capital of −346.3% in fiscal 2025. It ended the year with $28.9 million of debt and $16.4 million in cash and short-term investments, net debt of $12.5 million.
See the SNTI income statement, the SNTI chart for price history, or the SNTI stock overview for the latest quote and news.
SNTI key metrics FAQ
What is Senti Biosciences's return on equity?
Senti Biosciences's return on equity (ROE) was −393.4% in fiscal 2025: net income of -$61.4 million on average shareholders' equity of $15.6 million.
What is Senti Biosciences's ROIC?
Senti Biosciences's return on invested capital was −346.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Senti Biosciences have?
Senti Biosciences had total debt of $28.9 million at the end of fiscal 2025, a debt-to-equity ratio of 5.17.
What is Senti Biosciences's current ratio?
Senti Biosciences's current ratio was 1.67 at the end of fiscal 2025: current assets were 1.67 times current liabilities.